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Abstract The carotenoids lutein and zeaxanthin are be-
lieved to protect the human macula by absorbing blue light
and quenching free radicals. Intestinal malabsorption
syndromes such as celiac and Crohn’s disease are known
to cause deficiencies of lipid-soluble nutrients. We hypo-
thesized that subjects with nutrient malabsorption syn-
dromes will demonstrate lower carotenoid levels in the
macula and blood, and that these lower levels may correlate
with early-onset maculopathy. Resonance Raman spectro-
graphic (RRS) measurements of macular carotenoid levels
were collected from subjects with and without a history of
malabsorption syndromes. Carotenoids were extracted from
serum and analyzed by high performance liquid chroma-
tography (HPLC). Subjects with malabsorption (n=22) had
37% lower levels of macular carotenoids on average versus
controls (n=25, P<0.001). Malabsorption was not associ-
ated with decreased serum carotenoid levels. Convincing
signs of early maculopathy were not observed. We
conclude that intestinal malabsorption results in lower
macular carotenoid levels.
Keywords Macularcarotenoids.Lutein.Zeaxanthin.
Xanthophylls.Malabsorption
Introduction
Age-related macular degeneration (AMD) is the most
common cause of irreversible blindness among elderly
populations in the developed world [1]. A growing body of
evidence suggests that AMD is in part a nutritional disease
[2–9]. The nutritional basis for AMD is rooted in the theory
that macula-specific dietary antioxidants quench reactive
oxygen species and filter out high-energy blue light [9].
Studies have identified the fat-soluble carotenoids lutein
and zeaxanthin as important components of the antioxidant
protective system of the human macula [10].
Resonance Raman spectroscopy (RRS) is a novel technol-
ogy for the objective, noninvasive measurement of macular
carotenoids. We have shown previously that patients with
AMD on average register 32% lower concentrations of macular
pigment versus controls as measured by RRS [11] .Ar e v i e wo f
this technology has been published previously [12].
Malabsorption syndromes comprise a group of disorders
that result in diarrhea, steatorrhea, and/or malnutrition.
Causes of malabsorption include celiac disease, inflamma-
tory bowel disease (Crohn’s disease and ulcerative colitis),
cystic fibrosis, short bowel syndrome, pancreatitis, and
infection. Studies suggest that malabsorption syndromes
may lead to a state of chronic oxidative stress [13–15]. It is
possible that such stress leads to increased incidence of
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but such a correlation has not yet been established.
Little has been written on the effect of nutrient
malabsorption syndromes on the eye. Vitamin A (also fat
soluble) dominates what literature there is, and a deficiency
of this vitamin was most likely the first defined eye disease
from malabsorption [16]. Of note, an early case report
observed night-blindness and vitamin A deficiency after
jejeunoileal bypass [17]. In 2000, a case report documented
vitamin A deficiency in a patient with celiac disease, and a
larger study demonstrated low serum carotene concentra-
tions in patients with Crohn’s disease [18, 19]. In an
exploratory survey of patients with early-onset drusen
(under 50 years old), reported in abstract form, the current
authors observed that two of 11 participants had a
concomitant malabsorption syndrome [20]. Given that even
the earliest signs of maculopathy are found in fewer than
1% of the population under 50 years of age [21], these
findings suggested a potential connection between nutrient
deficiency states and overt maculopathy. We propose that
patients with malabsorption syndromes may suffer an
ocular deficiency of macular pigment. Macular pigment
deficiency could lead to increased risk of maculopathy in
younger populations, as it may accelerate the oxidative
processes that normally become manifest only with advanced
age. In the current study, we evaluate carotenoid concen-
trations in serum and maculae of patients with malabsorption
syndromes using objective RRS technology. Additionally,
we explore whether malabsorption may correlate with
clinically observable early-onset maculopathy.
Materials and methods
Experimental design
This is a controlled cross-sectional study that measures
macular and serum carotenoids as well as the presence of
drusen in both study groups at a given point in time.
Subjects
This study was approved by the University of Utah
Institutional Review Board, and all subjects signed institu-
tionally approved informed consent forms that complied
with the tenets of the Declaration of Helsinki. Control
subjects were recruited from the clinic population of the
Moran Eye Center at the University of Utah, School of
Medicine. Subjects with malabsorption syndromes were
recruited during the same time period by approved searches
of the University of Utah Hospital electronic chart database
for relevant ICD-9 codes. Patients with matching codes
were contacted by mail and invited to participate on a
voluntary basis. Additional subjects were referred by
physicians in the Department of Gastroenterology at the
same institution and from community support groups for
malabsorption patients. Subjects with and without malab-
sorption syndromes participated in all study procedures. All
subjects were under 58 years of age. A basic medical
history including history of family eye disease, nutritional
supplementation, and smoking was obtained from each
subject. Visual acuity was assessed, and eyes were dilated
using 2.5% phenylephrine HCl and 1% tropicamide
ophthalmic solutions 15–20 min prior to measurements,
and a dilated eye examined to exclude ocular pathology.
RRS measurements of human macular carotenoids
We used ocular resonance Raman spectroscopy to measure
human macular carotenoid concentrations. Details of the
instrumentation have been described elsewhere [11, 12]. For
a typical measurement, a 0.5-mW argon laser (488 nm) is
directed as a 1-mm spot onto the subject’s macula for 0.5 s
through a series of lenses and filters after pupil dilation of
>6 mm has been achieved. The subjects self-align by
superimposing the blue-green pilot laser beam on an array
of collection fibers illuminated with a red light-emitting-diode
(LED). Raman backscattered light is collected by a fiber optic
collection bundle and analyzed by a Raman spectrometer.
Raman carotenoid peaks identifying lutein and zeaxanthin are
obtained at 1,159 cm
−1 and 1,525 cm
−1 with a good signal-to-
noise ratio when the laser excitation beam is aimed at the
fovea. The peak height at the carotenoid carbon–carbon
double-bond stretch frequency of 1,525 cm
−1 is quantified
after subtraction of background fluorescence by Windows-
based computer software (Eye-C-Spec; Spectrotek, LC, Salt
Lake City, Utah). The Raman signal intensity was expressed
as Raman counts. Because subjects occasionally blink or
misalign, the mean±standard deviation (SD) of the highest
three of five measurements was used for statistical analysis
[11, 12]. Only one self-selected eye was dilated and measured
by RRS for each subject.
Serum carotenoid extraction
Approximately 5 ml of nonfasting venous blood was drawn
from each subject into serum separating tubes (BD, San Jose,
CA). Blood samples were centrifuged at 5,000 rpm for 5 min
at 4°C, and then the serum was removed and immediately
stored at −75°C until analysis. Carotenoids (lipid soluble)
were extracted from 100 μl of serum based on previously
reported methods [22, 23]. Briefly, 100 μl of serum was
added to 200 μl 0.1% butylated hydroxytoluene (BHT) in
ethanol to precipitate the proteins, and then 500 μle t h y l
acetate was added to extract the carotenoids. The sample was
centrifuged at 2,000 ×g for 5 min at 4°C, and the supernatant
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500 μl ethyl acetate two more times and extracted with
500 μl hexane once. The collected supernatants were
combined and dried down under vacuum. The dried sample
was dissolved in 1 ml of 50% methanol and then extracted
with 500 μl of hexane three times. The collected super-
natants were then dried down and re-dissolved in 100 μlo f
running solvent prior to HPLC analysis. Fifty-microliter
samples were injected onto the HPLC system. All procedures
were performed under dim light and on ice if possible.
Chromatographic system and HPLC analysis
The analyses were performed on a HPLC system (Thermo
Scientific, San Jose, CA) equipped with an auto-sampler, a
UV/visible photodiode-array detector, and data analysis
software. The separations were performed on a cyano column
(Microsorb cyano 100 Å, 5 μm, 25 cm length×4.6 mm
internal diameter, Rainin Instrument Co., Woburn, MA). The
eluent consisted of a mixture of hexane (80%), methylene
chloride (19.4%), methanol (0.5%), and N,N-diisopropyle-
thylamine (0.1%). The monitoring wavelength was 450 nm,
and the column flow rate was 1.0 ml/min. The column
temperature was maintained at 20°C. The running time was
20 min for each injection, and quantitation was by external
reference standards of purified lutein and zeaxanthin. Sample
analyses were performed in duplicate, and the mean was
used for statistical analysis.
Fundus examinations
Fundus examinations were performed by retinal specialists
at the Moran Eye Center. Photographs of visualized drusen
were taken by the imaging team at the Moran Eye Center.
Statistical analysis
RRS and serum data were analyzed via linear regression
plots. Normal and malabsorption populations were compared
by analysis of variance (ANOVA), unpaired, two-tailed
Student’s t-tests, and Fisher exact tests as appropriate using
SigmaStat software (Jandel Scientific, San Rafael, CA).
Results
Study subjects
A total of 22 patients with malabsorption syndromes
participated in the study (18 with celiac disease and four
with Crohn’s disease). Of the celiac patients, 16 reported
receiving a definitive diagnosis from a gastroenterologist.
Two of the patients were self-diagnosed after improvement
with a gluten-free diet. All Crohn’s patients reported a
definitive diagnosis from a gastroenterologist. Twenty five
healthy subjects without a history of malabsorption partic-
ipated as controls. Controls were volunteers from the
greater Salt Lake City area and were excluded if they were
older than 55 years and/or had a malabsorption syndrome.
Two control subjects had unilateral blindness due to trauma
or neurofibromatosis. One celiac patient had membrano-
proliferative glomerulonephritis (dense deposit disease)
with associated widespread macular drusen. This subject
was not included in the RRS macular pigment analysis due
to possible confounding effects. No subjects had significant
cataracts or other ocular pathology. Table 1 summarizes the
study population characteristics showing that the two
groups were well matched (P>0.05 for all categories).
RRS measurements of macular carotenoids
On average, subjects with malabsorption syndromes
showed 37% lower concentrations of macular carotenoids
compared to control subjects (P=0.002) as measured by
RRS (Fig. 1). In both control and malabsorption groups,
concentrations of macular carotenoids declined with age,
consistent with previously published findings in the Utah
population using multiple macular pigment measurement
methods [11, 12, 24, 25]. The decrease in carotenoid
concentrations in malabsorption patients relative to controls
was consistent across age because the regression lines are
nearly parallel. There were no significant differences
between patients with Crohn’s and celiac disease when
analyzed separately. The lowest macular pigment concen-
tration in either group was found in a 27-year-old male with
poorly controlled Crohn’s disease. His RRS signal intensity
was approximately one third the normal concentration.
Serum carotenoid analysis
Because detailed dietary histories were beyond the scope of
this study, serum carotenoids were used as a biomarker of
systemic carotenoid concentrations [26, 27]. No significant
difference was seen in serum concentrations of lutein when
comparing groups (P>0.05), while serum zeaxanthin was
significantly higher in the malabsorption group (P=0.018;
Figs. 2 and 3). This difference was driven by the subjects
with celiac disease who had 70% higher serum zeaxanthin
concentrations than the normals (P=0.003; Fig. 4). Serum
concentrations of both carotenoids increased with age in
both groups (P=0.007 in normal group; P=0.15 in
malabsorption patients). The lowest concentrations of both
lutein (18 ng/ml) and zeaxanthin (8 ng/ml) measured in any
subject occurred in the same 27-year-old subject with
Crohn’s disease. These concentrations were 12% and 20%
of the normal average for lutein (167 ng/ml) and zeaxanthin
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21, which was also the lowest among subjects. No new
significant differences were observed when data were
stratified by race or sex.
Fundus examinations
Study subjects reported good ocular function in the tested
eyes. A single, intermediate-sized soft druse was observed
Fig. 1 RRS linear regression plot (a) and bar graph (b). The plot
shows consistently lower Raman counts across age in malabsorption
subjects (triangle points/solid line) versus normal subjects (circle
points/dotted line; P=0.002). In both groups, the counts decline with
age (P=0.20 in normal subjects; P=0.05 in malabsorption patients).
The bar graph compares Raman count averages in the both groups as
a whole (malabsorption shaded, normal black). Malabsorption
subjects registered 37% lower Raman counts on average compared
to normals (P<0.001)
Fig. 2 Serum lutein regression plot (a) and bar graph (b) obtained by
HPLC analysis. No difference in serum lutein concentrations were
observed between malabsorption (triangle points/solid line, shaded
bar) and normal subjects (circle points/dotted line, black bar, P>0.05)
Table 1 Patient population
characteristics
a
aThere were no statistical
differences between the normal
and malabsorption populations
for all categories (P>0.05)
bBMI available on 60% of
the malabsorption and normal
populations
Normal Malabsorption syndromes
Age (years; mean±SD) 32±9.7 38.7±11.4
Age range (years) 22–50 17–57
No. males 11 6
No. females 14 16
No. white persons 21 22
No. nonwhite persons 4 0
Current smokers 1 3
Past or nonsmokers 24 19
Eye color (blue; hazel/green; brown) 13;3;9 12;7;3
Dilated pupil size (mean±SD) 8±1 mm 8±1 mm
Median visual acuity 20/20 20/20
Visual acuity range 20/15–20/60 20/15–20/60
No. Crohn’s disease 0 4
No. celiac disease 0 18
Body mass index (BMI
b; mean±SD) 27.1±6.4 25.6±3.6
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macularabnormalities were notedinmalabsorptionpatients or
controls with the exception of the celiac patient with
membranoproliferativeglomerulonephritiswhohadnumerous
macular drusen.
Discussion
Our finding that adults with intestinal malabsorption
syndromes have decreased concentrations of macular
pigment correlates well with a recent study that reported
that patients with pancreatic insufficiency associated with
cystic fibrosis registered lower concentrations of macular
carotenoids in both serum and macula [28]. Despite the fact
that neither study demonstrated convincing maculopathy at
the time of examination, these patients certainly could be at
risk for ongoing long-term macular oxidative stress that
could predispose to AMD later in life.
Malabsorption in celiac disease results from mucosal
villous blunting secondary to a T-cell mediated autoimmune
response to ingested gluten (found in wheat, barley, rye,
and oats) in the lamina propria of the small intestine [29].
Celiac disease is well controlled by a gluten-free diet in the
majority of cases. Crohn’s disease can present anywhere in
the gastrointestinal tract from the mouth to the anus, and
manifestsinthe formofrecurrent,painful flaresofaccelerated
autoimmune attack of the intestinal mucosal barrier [30]. The
etiology is unknown, and the therapy is limited.
Unlike cystic fibrosis patients who have life-long,
difficult to manage malabsorption syndromes, our malab-
sorption subjects generally had normal or even elevated
serum concentrations of lutein and zeaxanthin. We propose
some explanations for these initially unexpected findings.
As mentioned above, celiac disease is widely known to be
readily controllable. By eating a gluten-free diet, patients
are able to achieve near complete remission of the disease,
including mucosal villous recovery [31]. Whereas symp-
tomatic relief usually occurs within two weeks, villous
recovery is unpredictable and may take months to years
[ibid]. Once recovery has taken place, there is no reason not
to believe that a celiac patient would resume normal
absorptive function. The majority of celiac subjects in the
present study reported good control of their disease for over
a year on a gluten-free diet. As such, we would expect their
serum carotenoid concentrations to be in the normal range
since serum concentrations typically equilibrate within
weeks of any dietary change. Ideally, to validate our initial
hypothesis of low serum carotenoid concentrations, we
would have had to have enrolled only newly diagnosed
celiac patients that had had minimal gluten-free diet control
prior to carotenoid measurements, but these subjects are
difficult to find. The higher than normal zeaxanthin
concentrations in controlled celiac patients may be attrib-
utable to their increased consumption of corn which is a
prominent part of a gluten-free diet and one of the richest
known sources of zeaxanthin [32]. One study observed that
subjects fed a corn-enriched diet for 15 weeks showed a
70% increase in serum zeaxanthin concentration [33].
Despite apparently normalized serum carotenoid concen-
trations in our malabsorption subjects, macular carotenoid
Fig. 4 Bar graph comparison of zeaxanthin concentrations. Crohn’s
patients are indicated by the diagonal brick-filled column, celiac
patients by the shaded grey column, and normal subjects by the black
column. On average, those with celiac disease had 70% higher serum
zeaxanthin concentrations relative to normals (P=0.003)
Fig. 3 Serum zeaxanthin regression plot (a) and bar graph (b)
obtained by HPLC analysis. The bar graph indicates serum
zeaxanthin is significantly higher in malabsorption subjects (triangle
points/solid line, shaded bar) versus normals (circle points/dotted line,
black bar, P=0.018) when grouped as a whole
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normals. In normal human populations, dietary intake and
serum lutein and zeaxanthin concentrations correlate only
modestly with macular carotenoid concentrations [6], and
evidence from studies in primates suggests that macular
pigment concentrations in the serum and the macula at a
given point in time are not well correlated [34]. Adult
monkeys that were fed a life-long, xanthophyll-free diet
retained the ability to absorb high quantities of these
compounds following supplementation (as manifested by a
rapid increase in serum concentrations of lutein and
zeaxanthin); however, at 1 year post-supplementation, these
same animals registered only half the amount of macular
pigment in the macula as primates fed a life-long stock diet.
It is not known whether macular concentrations ever
normalized in the former group. Such a finding suggests
the possibility that prolonged macular pigment deficiency
may somehow affect the efficiency with which these
pigments are transported to and concentrated in the macula.
It is also possible that the concentration of lutein and
zeaxanthin into macular tissue simply takes a long time—
possibly years. A 2-year study of human macular pigment
concentrations in the absence of dietary modification
concluded that macular lutein and zeaxanthin concentrations
were stable throughout the study period, despite seasonal
fluctuations in serum concentrations [35]. Months-long drops
in serum carotenoid concentrations yielded no significant
change in macular concentrations. Considered together, these
findings indicate that the movement of carotenoid into or out
of the macula is most likely a slow process that is unaffected
by acute fluctuations in serum concentrations. This makes
sense from an evolutionary perspective in that the most
advantageous biological system for protecting the macula
would function despite the variable availability of carotenoid-
rich food. We therefore suggest that there is a lag between the
resolution of serum carotenoid concentrations in patients with
malabsorption syndromes (which may resolve within weeks
of intestinal recovery) and macular carotenoid concentrations
(which may require years to reaccumulate after years of
deficiency). If these suppositions are true, they highlight the
importance of early detection and monitoring of macular
pigment deficiency, and they suggest that extended use of
supplements may be required to reduce a patient’ss u s c e p t i -
bility to oxidative damage.
Serum lutein and zeaxanthin increased significantly with
age in normal subjects. This finding contrasts with the age-
related decline in macular pigment noted in the same
population. Adequate explanation for this observation is
beyond the scope of this study. The molecular biology of
carotenoid absorption, transport, and concentration with
specificity to the macula is not well understood. One
possible explanation is that an age-related breakdown in
these pathways causes a decrease in the efficiency with
which dietary carotenoids are taken up by the macula. If
such is the case, a vegetable rich diet and/or carotenoid
supplements may appreciably raise serum concentrations
without a corresponding rise in the macula. Our population
reported very little xanthophyll supplementation. Strict food
histories including type and quantity of vegetable con-
sumption were not obtained.
The markedly low concentrations of macular pigment
detected across the board in one Crohn’s patient indicate
that this condition may produce a more severe, less
controllable carotenoid deficiency than celiac disease. By
subjective judgment and patient self-report, we deemed this
patient to have the most poorly controlled malabsorptive
disease. He reported poor Crohn’s control on systemic
steroids and frequent flares. He also smoked regularly (1/2
packs per day, ppd). Studies suggest that up to 85% of
Crohn’s patients admitted to the hospital for exacerbations
have some degree of nutrient deficiency [36]. The percent-
age was 25% in the outpatient setting [37].
In summary, the present study offers further support for the
potential for macular pigment deficiency in patients with
malabsorptionsyndromes.Wesuggestthatserumandmacular
concentrations of these pigments are unlikely to be correlated
and may vary depending on the underlying malabsorption
syndrome and the degree to which it is controlled. Additional
studyofalargersampleofmalabsorptivepatientsiswarranted
to examine long-term risk of AMD. Such a study would be
most effective in close collaboration with gastroenterologists
to obtain data from subjects at the time of diagnosis and prior
to any treatment measures.
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